期刊
PHARMACOGENOMICS
卷 21, 期 8, 页码 509-520出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2020-0010
关键词
chromatin immunoprecipitation sequencing; enhancer elements; GDF15; histone marks; intergenic regions; metformin; SNPs; transcriptional regulatory elements; type 2 diabetes
资金
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-Brazil)
- CAPES-Brazil
- Young Talent Attraction Fellowship (BJT) from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-Brazil)
Aim: GDF15 levels are a biomarker for metformin use. We performed the functional annotation of noncoding genome-wide association study (GWAS) SNPs for GDF15 levels and the Genotype-Tissue Expression (GTEx)-expression quantitative trait loci (eQTLs) for GDF15 expression within metformin-activated enhancers around GDF15. Materials & methods: These enhancers were identified using chromatin immunoprecipitation followed by sequencing data for active (H3K27ac) and silenced (H3K27me3) histone marks on human hepatocytes treated with metformin, Encyclopedia of DNA Elements data and cis-regulatory elements assignment tools. Results: The GWAS lead SNP rs888663, the SNP rs62122429 associated with GDF15 levels in the Outcome Reduction with Initial Glargine Intervention trial, and the GTEx-expression quantitative trait locus rs4808791 for GDF15 expression in whole blood are located in a metformin-activated enhancer upstream of GDF15 and tightly linked in Europeans and East Asians. Conclusion: Noncoding variation within a metformin-activated enhancer may increase GDF15 expression and help to predict GDF15 levels.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据